Literature DB >> 17676311

Gradual reactivation of vascular angiotensin I to angiotensin II conversion during chronic ACE inhibitor therapy in patients with diabetes mellitus.

D C Sharman1, A D Morris, A D Struthers.   

Abstract

AIMS/HYPOTHESIS: In chronic heart failure there is gradual reactivation of vascular tissue angiotensin I (AI) to angiotensin II (AII) conversion over time in patients taking chronic ACE inhibitor therapy. However, it remains unknown whether the same overall phenomenon occurs in other patients taking chronic ACE inhibitor therapy, such as patients with type 2 diabetes mellitus.
METHODS: We studied 30 patients with type 2 diabetes mellitus (mean age 43.5 +/- 10.8 years), all of whom received lisinopril (20 mg/day) as part of their normal treatment. Over the course of the 18 month study, we made measurements at 0, 9 and 18 months. These measurements included plasma values for components of the renin-angiotensin-aldosterone system. In addition, we infused AI and AII into the brachial arteries of patients to assess vascular tissue AI to AII conversion.
RESULTS: There were no significant changes in plasma renin activity, ACE, AI, AII or aldosterone during the study. In contrast, vascular AI to AII conversion was significantly (p = 0.01) greater at 18 months than at 0 months. There was no change over time in the response to infused AII. CONCLUSIONS/
INTERPRETATION: We have shown in vivo that vascular tissue AI to AII conversion gradually increases over time in patients with type 2 diabetes being treated with lisinopril. Further studies are required to determine whether this reactivation detracts from the cardioprotective effects of chronic ACE inhibitor therapy in diabetic patients, and if so, how best to overcome it.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17676311     DOI: 10.1007/s00125-007-0754-5

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  20 in total

1.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

2.  Local inhibition of converting enzyme and vascular responses to angiotensin and bradykinin in the human forearm.

Authors:  N Benjamin; J R Cockcroft; J G Collier; C T Dollery; J M Ritter; D J Webb
Journal:  J Physiol       Date:  1989-05       Impact factor: 5.182

3.  Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease.

Authors:  M C Petrie; N Padmanabhan; J E McDonald; C Hillier; J M Connell; J J McMurray
Journal:  J Am Coll Cardiol       Date:  2001-03-15       Impact factor: 24.094

4.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

Authors: 
Journal:  Lancet       Date:  2000-01-22       Impact factor: 79.321

5.  Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study.

Authors:  C E Mogensen; S Neldam; I Tikkanen; S Oren; R Viskoper; R W Watts; M E Cooper
Journal:  BMJ       Date:  2000-12-09

6.  How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure?

Authors:  R J MacFadyen; A F Lee; J J Morton; S D Pringle; A D Struthers
Journal:  Heart       Date:  1999-07       Impact factor: 5.994

7.  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Lars H Lindholm; Hans Ibsen; Björn Dahlöf; Richard B Devereux; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Krister Kristiansson; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Peter Aurup; Jonathan Edelman; Steven Snapinn
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

8.  Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial.

Authors:  Naoyuki Nakao; Ashio Yoshimura; Hiroyuki Morita; Masyuki Takada; Tsuguo Kayano; Terukuni Ideura
Journal:  Lancet       Date:  2003-01-11       Impact factor: 79.321

9.  Lack of relationship between the short-term hemodynamic effects of captopril and subsequent clinical responses.

Authors:  B M Massie; B L Kramer; N Topic
Journal:  Circulation       Date:  1984-06       Impact factor: 29.690

10.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

Authors:  Marc A Pfeffer; John J V McMurray; Eric J Velazquez; Jean-Lucien Rouleau; Lars Køber; Aldo P Maggioni; Scott D Solomon; Karl Swedberg; Frans Van de Werf; Harvey White; Jeffrey D Leimberger; Marc Henis; Susan Edwards; Steven Zelenkofske; Mary Ann Sellers; Robert M Califf
Journal:  N Engl J Med       Date:  2003-11-10       Impact factor: 91.245

View more
  3 in total

1.  Mass spectrometry for the molecular imaging of angiotensin metabolism in kidney.

Authors:  Nadja Grobe; Khalid M Elased; David R Cool; Mariana Morris
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-02-07       Impact factor: 4.310

2.  Pharmacodynamic Impact of Carboxylesterase 1 Gene Variants in Patients with Congestive Heart Failure Treated with Angiotensin-Converting Enzyme Inhibitors.

Authors:  Karl Emil Nelveg-Kristensen; Peter Bie; Laura Ferrero; Ditte Bjerre; Niels E Bruun; Martin Egfjord; Henrik B Rasmussen; Peter R Hansen
Journal:  PLoS One       Date:  2016-09-23       Impact factor: 3.240

Review 3.  Liver disease and the renin-angiotensin system: recent discoveries and clinical implications.

Authors:  John S Lubel; Chandana B Herath; Louise M Burrell; Peter W Angus
Journal:  J Gastroenterol Hepatol       Date:  2008-06-28       Impact factor: 4.029

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.